Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Marimed (MRMD) Net Margin (2016 - 2025)

Marimed (MRMD) has disclosed Net Margin for 15 consecutive years, with 7.24% as the latest value for Q3 2025.

  • On a quarterly basis, Net Margin fell 480.0% to 7.24% in Q3 2025 year-over-year; TTM through Sep 2025 was 11.37%, a 247.0% decrease, with the full-year FY2024 number at 7.7%, up 306.0% from a year prior.
  • Net Margin was 7.24% for Q3 2025 at Marimed, down from 3.21% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 23.3% in Q2 2021 to a low of 26.04% in Q4 2023.
  • A 5-year average of 1.59% and a median of 2.56% in 2023 define the central range for Net Margin.
  • Biggest YoY gain for Net Margin was 4880bps in 2021; the steepest drop was -5146bps in 2021.
  • Marimed's Net Margin stood at 20.61% in 2021, then skyrocketed by 164bps to 13.25% in 2022, then crashed by -296bps to 26.04% in 2023, then grew by 19bps to 21.13% in 2024, then surged by 66bps to 7.24% in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Net Margin are 7.24% (Q3 2025), 3.21% (Q2 2025), and 14.28% (Q1 2025).